Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma
- 24 April 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (15), 4080-4092
- https://doi.org/10.1158/1078-0432.ccr-19-3714
Abstract
Purpose: Diffuse intrinsic pontine glioma (DIPG) bears a dismal prognosis. A genetically engineered brainstem glioma model harboring the recurrent DIPG mutation, ACVR1-G328V (mACVR1), was developed for testing an immune-stimulatory gene therapy. Experimental Design: We utilized the Sleeping Beauty transposase system to generate an endogenous mouse model of mACVR1 brainstem glioma. Histology was used to characterize and validate the model. We performed RNAseq analysis on neurospheres (NS) harboring mACVR1. mACVR1 NS were implanted into the pons of immune competent mice to test the therapeutic efficacy and toxicity of immune stimulatory gene therapy using adenoviruses expressing thymidine kinase (TK) and fms-like tyrosine kinase 3 ligand (Flt3L). mACVR1 NS expressing the surrogate tumor antigen ovalbumin were generated to investigate if TK/Flt3L treatment induces the recruitment of tumor-antigen specific T cells. Results: Histological analysis of mACVR1 tumors indicates that they are localized in the brainstem and have increased downstream signaling of bone morphogenetic pathway as demonstrated by increased phospho-smad1/5 and Id1 levels. Transcriptome analysis of mACVR1 NS identified an increase in the transforming growth factor beta (TGF-β) signaling pathway and the regulation of cell differentiation. Adenoviral delivery of TK/Flt3L in mice bearing brainstem gliomas resulted in anti-tumor immunity, recruitment of anti-tumor specific T cells and increased median survival. Conclusions:This study provides insights into the phenotype and function of the tumor immune microenvironment in a mouse model of brainstem glioma harboring mACVR1. Immune stimulatory gene therapy targeting the hosts' anti-tumor immune response inhibits tumor progression and increases median survival of mice bearing mACVR1 tumors.Keywords
Other Versions
Funding Information
- NIH National Institute of Neurological Disorders and Stroke NINDS (R37-NS094804, R01-NS105556, R21-NS107894)
- NIH NINDS (R01-NS076991, R01-NS082311, R01-NS096756)
- NIH NIBIB (R01-EB022563)
- RNA Biomedicine (F046166)
- NIH NINDS (F31NS103500)
- NIH NCI (T32-CA009676)
This publication has 72 references indexed in Scilit:
- Structure of the Bone Morphogenetic Protein Receptor ALK2 and Implications for Fibrodysplasia Ossificans ProgressivaJournal of Biological Chemistry, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Glioma cancer stem cells induce immunosuppressive macrophages/microgliaNeuro-Oncology, 2010
- Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult DiseaseJournal of Clinical Oncology, 2010
- Trafficking of immune cells in the central nervous systemJCI Insight, 2010
- Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor RegressionClinical Cancer Research, 2009
- Bone morphogenetic protein receptors and signal transductionThe Journal of Biochemistry, 2009
- Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and NeurotoxicityClinical Cancer Research, 2009
- De novo Induction of Genetically Engineered Brain Tumors in Mice Using Plasmid DNACancer Research, 2009